|Healthcare Review: Terra Tech, ZS Pharma, Amedisys, Insys Therapeutics, TherapeuticsMD|
|By Staff and Wire Reports|
|Tuesday, 08 July 2014 13:39|
Amedisys ($AMED) reports that the SEC advised the company that it had completed its investigation into the firm's operations and participation in the Medicare program and does not intend to pursue any enforcement action.
Insys Therapeutics ($INSY) plans to file an NDA this quarter for Dronabinol Oral Solution for the treatment of chemotherapy-induced nausea and vomiting and for the treatment of anorexia in patients with AIDS.
Shares of TherapeuticsMD ($TXMD) are up 30% on robust volume in apparent response to FBR Capital's Outperform rating and $34 PT, representing almost a seven-fold increase from the current price. The company focuses on women's health, specifically hormone replacement therapies. Its four lead products in development are TX 12-001HR (estradiol + progesterone) for hormone replacement and to treat the symptoms of menopause; TX 12-002HR (progesterone) for the treatment of amenorrhea; TX 12-003HR (estradiol) for the treatment of moderate-to-severe vasomotor symptoms due to menopause and TX 12-004HR (estradiol) for the treatment of vulvar and vaginal atrophy in postmenopausal women.